Navigation Links
Clinverse’s ClinPay Automated Solution Streamlines Investigator Payment Process for a Biotechnology Innovator
Date:10/23/2013

Raleigh, NC (PRWEB) October 23, 2013

Clinverse, Inc., provider of the first end-to-end, cloud-based financial lifecycle system for automating global clinical payments, announced today that Naurex Inc. has implemented ClinPay® to automate investigator payments for a current Phase II trial.

Naurex, a clinical-stage company developing treatments to address unmet needs in psychiatry and neurology, implemented ClinPay for a Phase II trial of its investigational antidepressant agent, GLYX-13. The trial is expected to enroll subjects at up to 25 sites across the US.

Naurex’s VP of Finance, Jim Schulz, was focused on finding an automated payment solution that would allow the biotech company to have complete control over its financials, including payments, invoicing, and cash management. According to Schulz, “As a smaller company, having a system in place that allows us real-time visibility into our financial outlook is an important time and resource saver, and in turn gives us a higher level of confidence as we move forward in our trial.”

In addition, drug development teams at companies such as Naurex require solutions that can efficiently address several other key financial management issues:

1.    Ability to generate benchmark data for financial trending and forecasting for future trials – predicting how much and when the company will be spending cash in future studies.
2.    Level of control over financial data that leads to significant time saving and resource efficiencies.
3.    Ability to ensure timely and accurate payments to sites, which result in better performing, higher enrolling, and more satisfied sites.

ClinPay’s open application programming interface (API) provides seamless integration with existing external systems, such as the EDC system used by Naurex and other biomedical firms. When data is captured in the EDC system, those clinical activities are matched to relevant contract terms in ClinPay, triggering payment transactions, which can be reviewed online and then automatically routed for payment. Clients also rely on reports directly from ClinPay to help complete month-end accounting. ClinPay’s fully validated accounting system also provides automated GAAP standards and compliance, automated contract amendments, and full audit trail capabilities.

“In the past, our old system required an 8-10 hour manual process on a monthly basis to reconcile payments,” noted Schulz. “With ClinPay, at the simple push of a button, a report is generated which shows how much we owe each site. What used to be a cumbersome process has been streamlined to a 5-minute process, providing us with definitive results that show our real-time, true liabilities.”

ClinPay’s patent-pending contract meta language (CML) converts contracted payment terms, regardless of complexity, into actionable items triggered by clinical activity, without further programming required. With these capabilities, sponsors can expect to reduce costs and manual efforts required to pay sites and other vendors by as much as 30-40% or more.

“The ability to pay our sites accurately and more frequently, even when managing very complex payment terms and guidelines, has changed our site relationships for the better,” said Kamran Alam, Director of Finance at Naurex.

Based on the success of the ClinPay implementation with the current Phase II trial, Naurex plans to use ClinPay in an upcoming Phase III trial.

About Clinverse, Inc.
Clinverse, Inc. offers the industry’s first end-to-end, cloud-based financial lifecycle system for automating clinical payments globally. Used by leading BioPharma companies, our clients benefit from reduced costs through automated financial processing and unprecedented transparency and workflow. Powered by our highly secure technology platform, our solution manages millions of global financial transactions in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11253783.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
2. IMDx Obtains CE-Marking for an Automated Molecular Test for Detection and Differentiation of Herpes Simplex Viruses 1 and 2
3. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
4. Automated Online Sample Preparation Comes to Waters UltraPerformance Liquid Chromatography (UPLC) Platform
5. Automated design for drug discovery
6. Used-Line.com's Automated ‘Wanted-List System’ Matches Test Equipment Wanted Lists with Dealer Inventory; Beta Version Open for All Test Equipment Dealers
7. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
8. Fast Motorized Fiber-Positioner for Automated Alignment Applications in Data-Communication, Photonics Offered by PI
9. Peptide Machines, Inc. Introduces New High-Quality, Cost-Efficient, Fully Automated Multiple Peptide Synthesizer with Preactivation
10. Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers
11. Gated STED -- developing the next generation of super-resolution microscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):